綠葉製藥(02186.HK):投資者擬向深圳綠葉投資最多16億元
格隆匯7月23日丨綠葉製藥(02186.HK)發佈公吿,2024年7月22日,投資者、賣方(康海醫藥、Hong Kong Luye及峯懋集團的統稱)及綠葉訂約方(公司、深圳綠葉、南京綠葉、煙台綠葉、山東綠葉及劉殿波先生)訂立投資協議,據此,投資者有條件同意向深圳綠葉(綠葉製藥(深圳)有限公司,公司的附屬公司)投資最多人民幣16億元,投資將分為若干步驟逐步實施。投資完成後,投資者將持有深圳綠葉合計34.8%的股權。根據投資協議,投資者獲授回購期權,該回購期權賦予投資者要求綠葉訂約方回購投資者於目標公司(深圳綠葉及南京綠葉)的全部持股的權利。
投資者(即深圳市綠葉私募股權投資基金合夥企業(有限合夥))在中國註冊,其基金管理人為深圳市投控資本有限公司,而深圳市投控資本有限公司由深圳市投資控股有限公司全資擁有,其最終實益擁有人為深圳市人民政府國有資產監督管理委員會。投資者的主要業務是以私募基金從事股權投資、投資管理、資產管理等活動(須在中國證券投資基金業協會完成登記備案後方可從事經營活動,而依法須經批准的項目,經相關部門批准後方可開展經營活動)。煙台綠葉為投資者的有限合夥人,持有其9%權益。
投資事項的所得款項將主要用作集團腫瘤業務的持續發展。該等資金的戰略部署預期將增強深圳綠葉的市場競爭優勢,並促進持續、穩定增長。憑藉投資事項,集團將加強下一代創新抗癌藥物的開發,並在市場準入、營銷及合作等領域協助業務增長,從而加速集團腫瘤業務進入高質量增長階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.